Skip to content
DataLookout
Menu

NCT06502691

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 31, 2027 to Dec 31, 2028 Show 5 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Study completion pushed from Dec 31, 2030 to Dec 31, 2031
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
    • Site details revised
  2. Minor Start date changed from estimate of Mar 1, 2026 to Feb 26, 2026v13
  3. Minor Start date: Feb 1, 2026 to Mar 1, 2026v12
  4. Notable Start date: Jan 1, 2026 to Feb 1, 2026v11
  5. Notable Start date: Nov 22, 2025 to Jan 1, 2026v10
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Primary completion date: Dec 31, 2026 to Dec 31, 2027
    • Study completion date: Dec 31, 2029 to Dec 31, 2030
    v9
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 1, 2026 to Nov 22, 2025
    • Site details revised
    v8
  3. Notable Start date: Oct 1, 2025 to Jan 1, 2026v7
  4. Notable Start date: Jul 1, 2025 to Oct 1, 2025v6
  5. Notable Start date: Apr 1, 2025 to Jul 1, 2025
    • Site contact updated
    v5
  6. Notable Start date: Jan 9, 2025 to Apr 1, 2025v4
  7. Notable Start date: Dec 1, 2024 to Jan 9, 2025v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall response rate (ORR)
Timeframe: Baseline up to 6 months

Secondary (1)

ORR

Arms and interventions

Arm I ([18F]FTT PET, FDG PET/CT, PARP inhibitor, ICI)Experimental

Patients receive \[18F\]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy and again at 12 weeks. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening and during follow up.

Arm II ([18F]FTT PET, FDG PET/CT, PARP inhibitor, ICI)Active comparator

Patients receive \[18F\]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening.

Other: Best Practice, Electronic Health Record Review, Fludeoxyglucose F-18

Procedures: Biopsy of Breast, Computed Tomography, Positron Emission Tomography

Radiation: Fluorine F 18 Fluorthanatrace

Drugs: Immune Checkpoint Inhibitor, Poly (ADP-Ribose) Polymerase Inhibitor

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States